Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04215861

Enrollment

1000

Registered

2020-01-02

Start date

2019-10-01

Completion date

2021-10-31

Last updated

2020-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Liver Cancer, Lung Cancer, Stomach Cancer

Brief summary

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.

Detailed description

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* 18-80 years old; * The patient whose tumor (tissue or cell) was first diagnosed by pathology; * Plan to receive routine clinical treatment: chemotherapy, radiotherapy, surgery, intervention, targeted therapy, traditional Chinese medicine treatment and biological immunotherapy; * Have relevant indications for treatment and have no contraindications;

Exclusion criteria

* Severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, heart, liver or kidney diseases, etc.); * Other circumstances considered inappropriate by the researcher to participate in the study;

Design outcomes

Primary

Measure	Time frame	Description
Raman spectra	the 1st day before operation	Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected to analyze the signal changes of Raman spectrum

Secondary

Measure	Time frame
progression-free survival	through study completion, an average of 1 year
overall survival	through study completion, an average of 1 year
objective response rate	through study completion, an average of 1 year

Countries

China

Contacts

Primary ContactXiaonan Cui, MD,PhD

cxn23@sina.com+8618098876725

Outcome results